TG Therapeutics Initiates Patient Enrolment in P-III ULTRA-V Trial for Triple Combination Regimen to Treat R/R Chronic Lymphocytic Leukemia
Shots:
- The company has initiated patient enrolment in P-III ULTRA-V trial evaluating Ukoniq + ublituximab + venetoclax- vs Ukoniq + ublituximab (U2) in patients with both frontline and r/r CLL. The 1EPs of the trial is PFS
- The company reports the completion of patient enrolment in the P-II ULTRA-V trial evaluating the triple combination of U2 + venetoclax in 165 patients with front line CLL- r/r CLL who were refractory to prior BTK therapy. The 1EPs of the trial is ORR and CRR
- The company launch a P-III study based on the P-I clinical results. Additionally- the initial results from the P-II ULTRA-V trial are expected in 2022
Ref: TG Therapeutics | Image: Seeking Alpha
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com